RxDoctor Payments Data

Eric Gravois, MD

Family Medicine · Pierre Part, LANPI 1467746628

Payments from drug & device makers

$346in general payments, 2019–2025

Across 24 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$163
  • Pfizer$97
  • Takeda Pharmaceuticals U.S.A., Inc.$26
  • Novo Nordisk$22
  • Amgen$21
  • GSK$18

What the payments were for

  • Food & beverage$24571%
  • Education$10129%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)18$163
Pfizer2$97
Takeda Pharmaceuticals U.S.A., Inc.1$26
Novo Nordisk1$22
Amgen1$21
GSK1$18

How this compares

$346 in reported general payments places this provider in the 35th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$124,220
Medicare patients
235
Services billed
1,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin433$248,638
EliquisApixaban243$84,437
OzempicSemaglutide74$81,783
MounjaroTirzepatide76$79,100
JanuviaSitagliptin Phosphate45$37,958
TrulicityDulaglutide88$37,010
NuedextaDextromethorphan Hbr/Quinidine20$32,339
LinzessLinaclotide38$21,253
Spiriva RespimatTiotropium Bromide30$18,311
JanumetSitagliptin Phos/Metformin Hcl12$18,027
FarxigaDapagliflozin Propanediol22$16,432
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$15,153
Stiolto RespimatTiotropium Br/Olodaterol Hcl29$13,788
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,944
RestasisCyclosporine32$12,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$84,437243 claims
Novo NordiskOzempic$22$81,78374 claims
AbbVieLinzess, Restasis$163$33,73270 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$18$25,18944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Pierre Part

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →